Clovis Oncology, Inc. announces 144A offering of convertible senior notes.
On September 9, Willkie client Clovis Oncology, Inc. announced the closing of its offering of $287.5 million aggregate principal amount of its 2.50% convertible senior notes due 2021 in a Rule 144A offering to qualified institutional buyers.
Based in Boulder, CO, Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
Willkie previously represented Clovis Oncology in its IPO and several subsequent equity offerings. Willie has also represented Clovis Oncology in numerous acquisitions and licensing deals of products and businesses. The current transaction was handled by Thomas Mark, Peter Jakes, Christopher Peters, Michael Brandt, Angela Redai, Michal Flombaum and Meredith Levy.
